PLX articles & resources on Made-in-China.com

Pluristem Therapeutics Has Been Granted a New Patent by The Australian Patent Office

Feb 20, 2014

Pluristem Therapeutics, a developer of placenta-based cell therapies, has been granted a new patent by the Australian Patent Office. Patent #2007228341 covers the method and composition of matter for three-dimensional (3D) expansion of ...

Tags: 3D Cell Expansion, Pluristem

FCI Will Introduce Its Mini-SAS HD Active Optical Cable Assembly

Feb 8, 2014

FCI, a leading supplier of connectors and interconnect systems, will introduce its mini-SAS HD Active Optical Cable (MSHD AOC) assembly, the latest addition to its portfolio of optical and electrical cabling solutions, at DesignCon 2014. ...

Tags: MSHD AOC, EEPROM, PLX, FCI

IMH Has Approved Pluristem Therapeutics' Request to Start a Phase II Trial

Oct 9, 2013

The Israeli Ministry of Health (IMH) has approved Pluristem Therapeutics’ request to start a Phase II trial using its PLacental eXpanded (PLX) cells in the treatment of intermittent claudication (IC). IC is a subset of peripheral ...

Tags: clinical study, Medicine

Cha Bio&Diostech Has Filed Its First Investigational New Drug (IND) Application

Jul 10, 2013

Cha Bio&Diostech, a South Korean partner of Pluristem Therapeutics, has filed its first investigational new drug (IND) application for Pluristem’s PLacental eXpanded (PLX) cells with the Korean Food and Drug Administration (KFDA). ...

Tags: PLX Cells, Cha Bio&Diostech

The US FDA Has Granted Orphan Drug Designation to Treat Aplastic Anemia

Feb 25, 2013

The USFDA has granted orphan drug designation to Pluristem Therapeutics' PLacental eXpanded (PLX) cells to treat aplastic anemia. The failure of hematopoietic stem cells (HSCs) present in the bone marrow to produce red blood cells, white ...

Tags: orphan drug, aplastic anemia, drug

Pluristem Gained PEI Approval to Begin Phase I/II Study for Muscle Regeneration

Dec 6, 2012

Pluristem Therapeutics has gained Paul-Ehrlich-Institute (PEI) approval to begin Phase I/II study for muscle regeneration in Germany. The randomized, double blind, placebo controlled study will assess the safety and efficacy of its PLX ...

Tags: Paul-Ehrlich-Institute, PEI, PLX cells

Pluristem Therapeutics Is Seeking FDA Orphan Drug Status

Dec 4, 2012

Pluristem Therapeutics, a developer of placenta-based cell therapies, is seeking FDA orphan drug status for its PLacental eXpanded (PLX) cells for the treatment of aplastic anemia. Pluristem earlier received an orphan drug status from the ...

Tags: Pluristem Therapeutics, placenta-based cell therapies